Zhiying Qiu

Biostatistics Project Leader, Associate Director
Sanofi, Bridgewater, NJ, USA

Presentation(s):

• OC 40.3 - Consumption of On-demand Factor Concentrates and Bypassing Agents for Management of Breakthrough Bleeds with Fitusiran Prophylaxis in People with Haemophilia A or B: An Analysis of Two Phase 3 Studies

  Monday, July 11, 2022
  3:15 PM – 3:30 PM

• OC 50.2 - Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B Without inhibitors

  Tuesday, July 12, 2022
  11:00 AM – 11:15 AM

• PB1152 - Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B With Inhibitors

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM